Discover
RNAZ
TransCode Therapeutics, Inc.
3.79
32 x 3.79
1 x 3.80
bid
ask
-
0.09
2.32%
12:32 PM
timesize
| Ytd | -44.51% | |
| 1y | -65.51% |
3.59
day range
3.98
3.59
52 week range
20.99
| Open | 3.90 | Prev Close | 3.88 | Low | 3.59 | High | 3.98 | Mkt Cap | 4.01M |
| Vol | 11.40K | Avg Vol | 61.97K | EPS | -48.13 | P/E | -0.08 | Forward P/E | -5.97 |
| Beta | 1.24 | Short Ratio | 0.50 | Inst. Own | 1.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.12 | 200-d Avg | 8.19 | 1yr Est | 20.00 |
| Income Statement | |||
| Operating Expenses | 17.76M | ||
| Research and Development Expense | 15.53M | ||
| Selling, General and Administrative Expense | 2.22M | ||
| Operating Income | -17.76M | ||
| Income Tax Expense | 231.31K | ||
| Net Income | -17.79M | ||
| Net Income Common Stock | -19.51M | ||
| Net Income Common Stock (USD) | -19.51M | ||
| Consolidated Income | -17.79M | ||
| Earnings per Basic Share | -21.28 | ||
| Earnings per Basic Share (USD) | -21.28 | ||
| Earnings per Diluted Share | -21.28 | ||
| Earning Before Interest & Taxes (EBIT) | -17.55M | ||
| Earning Before Interest & Taxes (USD) | -17.55M | ||
| Preferred Dividends Income Statement Impact | 1.73M | ||
| Weighted Average Shares | 916.97K | ||
| Weighted Average Shares Diluted | 916.97K | ||
| Balance Sheet | |||
| Cash and Equivalents | 12.84M | ||
| Cash and Equivalents (USD) | 12.84M | ||
| Trade and Non-Trade Receivables | 638.00 | ||
| Current Assets | 16.75M | ||
| Property, Plant & Equipment Net | 346.75K | ||
| Total Assets | 157.16M | ||
| Current Liabilities | 5.38M | ||
| Total Liabilities | 12.64M | ||
| Accumulated Retained Earnings (Deficit) | -115.65M | ||
| Shareholders Equity | 1.25M | ||
| Shareholders Equity (USD) | 1.25M | ||
| Assets Non-Current | 140.42M | ||
| Deferred Revenue | 85.26K | ||
| Goodwill and Intangible Assets | 140.04M | ||
| Liabilities Non-Current | 7.27M | ||
| Trade and Non-Trade Payables | 5.29M | ||
| Tax Liabilities | 457.38K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 23.94K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -4.98M | ||
| Net Cash Flow from Operations | -4.98M | ||